Revamp Medical

Executive Summary

Revamp Medical is an Israeli med-tech company addressing a critical unmet need in acute heart failure (AHF) management. Its lead product, the Doraya catheter, is a minimally invasive, flow-reducing central venous device designed to temporarily lower central venous pressure, thereby improving diuretic efficacy and decongestion. By enhancing renal function, the catheter aims to reduce hospital stay duration and lower 30-day readmission rates. Current AHF treatments are limited by diuretic resistance and renal dysfunction, leading to prolonged hospitalizations and high recurrence. Revamp's approach offers a novel mechanical solution that could transform standard of care. The company is in Phase 1 development, with a small team of 10-50 employees. While no specific funding or valuation details are available, the technology has potential to address a large and growing market, as AHF represents a significant burden on healthcare systems worldwide.

Upcoming Catalysts (preview)

• Q4 2026Completion of First-in-Human Study Results70% success
• Q1 2027Series A Financing Round60% success
• Q2 2027FDA Breakthrough Device Designation50% success